● Recruiting

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Condition: Relapsing Multiple Sclerosis · Sponsor: Novartis Pharmaceuticals

PhasePhase 3

Planned participants360

Who can joinAll sexes, 40 Years to 70 Years

Healthy volunteersNo

About this study

The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).

This description comes directly from the study's public registry record.

Talk to the study team

Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com

Novartis Pharmaceuticals · +41613241111

Always discuss trial participation with your own doctor first.

Locations (120)

Perseverance Research Center	Scottsdale, Arizona, United States	Recruiting
University of California Irvine	Irvine, California, United States	Recruiting
Medstar Washington Hospital Center	Washington D.C., District of Columbia, United States	Recruiting
Neurology of Central FL Res Ctr	Altamonte Springs, Florida, United States	Recruiting
University of Florida	Gainesville, Florida, United States	Recruiting
Neurology Associates PA	Maitland, Florida, United States	Recruiting
Aqualane Clinical Research	Naples, Florida, United States	Recruiting
Advent Health Orlando	Orlando, Florida, United States	Recruiting
Orlando Health Clinical Trials	Orlando, Florida, United States	Recruiting
Tallahassee Neurological Clinic	Tallahassee, Florida, United States	Recruiting
University Of South Florida	Tampa, Florida, United States	Recruiting
Vero Beach Neurology	Vero Beach, Florida, United States	Recruiting

+ 108 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06846281